The FDA has delayed giving a decision on Sanofi-Pasteur's pediatric combination vaccine for technical reasons to November 2, according to the company.
Subscribe to our email newsletter
The vaccine is designed to prevent diphtheria, pertussis or whooping cough, polio, tetanus and Haemophilus influenzae type b. It is sold in nine countries including Canada. A spokesperson for Sanofi said that the delay was nothing to do with the vaccine itself, and said that it was a technical matter.
The FDA had asked Sanofi earlier in the year about the way it is conducting analysis in its new lab in the US, after moving production from Canada.